Galera-Obsidian Merger Closes, Leaving Legacy Stockholders with 1.2% Stake and Contingent Value Rights
Summary
Galera Therapeutics completed its merger with Obsidian Therapeutics, leaving legacy stockholders with a 1.2% stake in the combined company and contingent value rights for potential future payouts. The stock will be delisted.
Key Events · M&A and Partnerships · GRTXD
-
Merger Closed, Galera Stockholders Diluted
The reverse merger with Obsidian Therapeutics closed, giving legacy Galera stockholders only 1.2% of the combined company (730,057 shares out of ~61.7M total), while PIPE investors got 47.2% and Legacy Obsidian holders 51.6%.
-
Contingent Value Rights Issued
Galera stockholders received CVRs for 80% of net proceeds from any future licensing or sale of tilarganine (5-year term) and 95% from the prior Biossil asset sale (10-year term), but no payments are guaranteed.
-
Delisting and Deregistration
Galera's common stock will cease trading on the OTCQB, and the company will file a Form 15 to terminate its SEC reporting obligations, effectively ending its public company status.
-
Board and Management Replaced
All Galera directors and executive officers resigned at closing, replaced by Obsidian-affiliated officers, completing the change of control.
Analysis · GRTXD · Life Sciences
The merger between Galera Therapeutics and Obsidian Therapeutics closed on August 3, 2026, finalizing a reverse merger that leaves legacy Galera stockholders with only 1.2% of the combined company. The deal includes Contingent Value Rights (CVRs) entitling holders to 80% of net proceeds from Galera's legacy drug candidate tilarganine and 95% from a prior asset sale, but payments are uncertain and years away. Galera's stock will be delisted from the OTCQB, and its board and management have been replaced by Obsidian appointees. This is a transformative event that effectively ends Galera's independent existence and dramatically dilutes existing shareholders.
At the time of this filing, GRTXD was trading at $18.99 on OTC in the Life Sciences sector, with a market capitalization of approximately $22M. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.